Consistent with these findings, our study confirmed that VDR levels are elevated in gefitinib-resistant NSCLC cells and that VDR silencing mitigates gefitinib resistance both in vitro and in vivo. The gene discussed is VDR; the disease is non-small cell lung carcinoma.